Next Steps for Submitted Abstracts
Notifications will be sent in during the first two weeks of March (exact date will be posted here once known). Notifications will be from sender firstname.lastname@example.org. This is the same sender for all other ASMS transactions (membership dues receipt, registration receipt, abstract submission receipt.) If you have not already done so, please white list / make safe this sender (email@example.com).
March 12 is deadline presenting author changes and withdrawals for accepted abstracts. If for any reason the presenting author listed on the abstract is not able to make this presentation, you must contact ASMS (firstname.lastname@example.org) for approval to change the presenter (be sure to reference your abstract ID). New presenting author must not already be scheduled to present a poster or talk. If an accepted poster or talk must be withdrawn please contact email@example.com by March 12. Reference the abstract ID in email.
April 15 is the date for public availability of the final program for Atlanta. This will be available to all via the Online Planner.
Submitting authors may learn the status of their abstract by checking online.
Go to ASMS Abstract site and select 'View my Submissions and Drafts'. Select abstract by clicking the title, full abstract will display and session assignment information will appear in upper right corner.
Criteria for Abstract Acceptance
The ASMS Program Committee will meet to review abstracts. Abstracts must meet the following criteria:
- The results presented in each abstract should add something new to our base of knowledge in mass spectrometry. The novel aspect of your work is an important consideration during abstract review.
- The abstract should include sufficient results to properly represent the experiments that will be presented.
- There must be a fundamental difference between each of the abstracts submitted from a research group. The same results may not appear in multiple presentations.
- Each attendee can be the presenting author on only one abstract (although an individual may be listed as a co-author on multiple abstracts).
- Abstracts with substantial commercial content will not be accepted.
- Failure to disclose information, such as the ID of compounds, is not acceptable.